Xtandi

ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval
ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval
Fierce Pharma
Pfizer
Astellas
Xtandi
prostate cancer
ASCO 2019
Flag link:
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer
Fierce Pharma
Xtandi
Astellas
Pfizer
hormone-sensitive prostate cancer
Flag link:
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
CP Wire
Astellas
Pfizer
Xtandi
prostate cancer
metastatic prostate cancer
Flag link:
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
Astellas
Pfizer
Xtandi
prostate cancer
metastatic prostate cancer
Flag link:
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
BioCentury
Pfizer
Nektar Therapeutics
NKTR-214
Xtandi
Talzenna
Bavencio
prostate cancer
Flag link:
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Yahoo/Zacks.com
prostate cancer
JNJ
Zytiga
Erleada
Pfizer
Astellas
Xtandi
AbbVie
Lupron
Endocyte
Lu-PSMA-617
Flag link:
Pfizer, Astellas revise two cancer drug trial protocols to speed up results
Pfizer, Astellas revise two cancer drug trial protocols to speed up results
Yahoo/Reuters
Pfizer
Astellas
clinical trials
Xtandi
prostate cancer
Flag link:
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
Yahoo/Zacks.com
Pfizer
FDA
Astellas
Xtandi
prostate cancer
Flag link:
Can This Pharma's $14 Billion Bet Succeed?
Can This Pharma's $14 Billion Bet Succeed?
Motley Fool
Pfizer
M&A
Medivation
Xtandi
talazoparib
Flag link:
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Fierce Pharma
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
Flag link:
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
Flag link:
Pfizer, Astellas peg Xtandi expansion on PROSPER data
Pfizer, Astellas peg Xtandi expansion on PROSPER data
Biopharma Dive
Pfizer
Astellas
Xtandi
prostate cancer
Flag link:
Patent setback could sting J&J prostate cancer franchise
Patent setback could sting J&J prostate cancer franchise
Biopharma Dive
patents
JNJ
prostate cancer
Zytiga
Xtandi
Astellas
Flag link:
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK
Endpoints
Pfizer
JNJ
patents
Zytiga
Xtandi
prostate cancer
apalutamide
Flag link:
New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi
New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi
Endpoints
Pfizer
Astellas
clinical trials
Xtandi
prostate cancer
Flag link:
Astellas, Pfizer scrap a PhIII breast cancer study using Xtandi; New $30M fund will back Israeli biotech startups
Astellas, Pfizer scrap a PhIII breast cancer study using Xtandi; New $30M fund will back Israeli biotech startups
Endpoints
Astellas
Pfizer
breast cancer
clinical trials
Xtandi
Israel
biotech
Flag link:
Here's Why the Best Is Yet to Come for Pfizer Inc.
Here's Why the Best Is Yet to Come for Pfizer Inc.
Motley Fool
Pfizer
Eucrisa
Xtandi
Inflectra
Flag link:
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
Fierce Pharma
Pfizer
Xtandi
Medivation
Flag link:
Astellas inks biomarker deal to pinpoint Xtandi patients
Astellas inks biomarker deal to pinpoint Xtandi patients
BioPharma Dive
Astellas
Xtandi
biomarkers
patients
tumor profiles
Flag link:
The 3 Biggest Risks for Pfizer in 2017
The 3 Biggest Risks for Pfizer in 2017
Motley Fool
Pfizer
Xtandi
competition
patents
Lyrica
Celebrex
Flag link:

Pages